Table 4.
All‐cause and MCL‐related monthly healthcare costs per patient by number of unique AEs experienced
| Monthly healthcare cost per patient (USD)* | All‐cause cost | MCL‐related cost§ | ||||||
|---|---|---|---|---|---|---|---|---|
|
All pts‡ (N = 1768) |
1‐2 AEs (N = 680) |
3‐5 AE (N = 693) |
≥6 AEs (N = 200) |
All pts‡ (N = 1768) |
1‐2 AEs (N = 680) |
3‐5 AE (N = 693) |
≥6 AEs (N = 200) |
|
| Total cost | ||||||||
| Mean | $14 786 | $12 584 | $15 063 | $22 052 | $9267 | $8252 | $9165 | $11 003 |
| SD | $16 482 | $12 717 | $17 751 | $18 727 | $12 309 | $8667 | $13 247 | $13 474 |
| Median | $9637 | $8416 | $9147 | $16 022 | $5457 | $5024 | $5028 | $6473 |
| Hospitalization | ||||||||
| Mean | $4489 | $2046 | $5532 | $11 411 | $2399 | $962 | $3305 | $5159 |
| SD | $12 341 | $6824 | $13 973 | $14 214 | $9217 | $4432 | $10 631 | $8600 |
| Median | $0 | $0 | $937 | $6644 | $0 | $0 | $0 | $805 |
| ED visit | ||||||||
| Mean | $87 | $43 | $115 | $173 | $8 | $3 | $12 | $20 |
| SD | $334 | $122 | $481 | $307 | $72 | $33 | $88 | $118 |
| Median | $0 | $0 | $17 | $60 | $0 | $0 | $0 | $0 |
| Office visit | ||||||||
| Mean | $280 | $267 | $275 | $402 | $63 | $58 | $63 | $85 |
| SD | $491 | $700 | $217 | $482 | $155 | $201 | $116 | $136 |
| Median | $195 | $181 | $208 | $294 | $15 | $13 | $17 | $26 |
| Pharmacy | ||||||||
| Mean | $7094 | $7623 | $6235 | $6121 | $5645 | $6130 | $4700 | $4227 |
| SD | $6736 | $7552 | $5684 | $5027 | $5780 | $6159 | $4600 | $4641 |
| Median | $4955 | $5297 | $4622 | $4720 | $3774 | $4010 | $3160 | $2945 |
| Other services† | ||||||||
| Mean | $2835 | $2606 | $2906 | $3944 | $1152 | $1099 | $1085 | $1512 |
| SD | $3760 | $3580 | $3338 | $5526 | $2785 | $2432 | $2207 | $4860 |
| Median | $1714 | $1525 | $1820 | $2545 | $407 | $401 | $384 | $438 |
Abbreviations: AE, adverse event; ED, Emergency department; Pts, patients; SD, standard deviation; w/, with.
For patients receiving ibrutinib, HRU and costs were measured among ibrutinib patients without evidence of prior treatment before index.
Other services include laboratory and pathology, radiology, surgery, ancillary and all other outpatient services
All patients include patients with no new AEs during treatment and are patients who received at least one of the four most commonly observed MCL treatment regimens at some point during follow‐up, regardless of line of therapy (ie patient could be indexed on another MCL treatment).
MCL‐related utilization was defined as medical and inpatient claims with a diagnosis code for MCL at any positions or pharmacy and medical claims for MCL‐related treatments.